Real-world Outcomes in Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Consolidative Thoracic Radiation (cTRT) and Chemoimmunotherapy (CIT): A Population Level Study

A.J.W. Gibson
WCLC 2024 (abstract)
🔗 Full Publication

Development of a Novel Risk Stratification Model for Immune-Related Adverse Events for Patients with Advanced Melanoma and NSCLC Treated with ICIs

Yizhuo Kelly Gao
ASCO 2024 (abstract/full paper where available)
🔗 Full Publication

The Impact of the COVID-19 Pandemic on the Treatment Patterns of Patients with Stage III Unresectable NSCLC

Paolo Borghetti
ELCC 2024 / Annals of Oncology (abstract)
🔗 Full Publication

Real-world Survival with CRT → Durvalumab for Unresectable, Stage III NSCLC in Canada: The RELEVANCE Study

Paul Wheatley-Price (and collaborators)
WCLC 2023 (abstract)
🔗 Full Publication

Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA)

LJ Zhan
WCLC 2023 (abstract)
🔗 Full Publication

Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic NSCLC Cohort

S. Cook
WCLC 2023 (abstract)
🔗 Full Publication

Long-term Survivors with EGFR-Positive NSCLC Treated with TKIs: A Combined Canadian Cohort

H. Halperin
WCLC 2023 (abstract)
🔗 Full Publication

Characteristics, Treatment Patterns and Outcomes of Real-World NSCLC Exon 20 Insertions

A.J.W. Gibson
WCLC 2023 (abstract)
🔗 Full Publication

Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC

A.J.W. Gibson
WCLC 2023 (abstract)
🔗 Full Publication

Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-Positive NSCLC Receiving Targeted Therapy Following Immunotherapy

M.L. Dean
WCLC 2023 (abstract)
🔗 Full Publication

Prognostic and Treatment Characteristics of Metastatic KRAS G12C Mutant NSCLC

A. Elegbede
Journal of Thoracic Oncology. 2021;16(S10):S1159–S1160
🔗 Full Publication

Long Term Survival Characteristics in SCLC Patients Receiving Atezolizumab and Chemotherapy

A. Elegbede
Journal of Thoracic Oncology. 2021;16(S10):S1187–S1188
🔗 Full Publication

Efficacy and Safety of Crizotinib in Real-World ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort

A.J.W. Gibson
Journal of Thoracic Oncology. 2021;16(S10):S1090–S1091
🔗 Full Publication

Prognostic Nutritional Index in Real-World Patients Receiving Systemic Therapy for Driver Mutation-Positive Metastatic NSCLC

A.J.W. Gibson
Journal of Thoracic Oncology. 2021;16(S10):S1148
🔗 Full Publication

The Impact of Sex on Non-Small Cell Lung Cancer Survival in Canada

C. Ford-Sahibzada
Journal of Thoracic Oncology. 2021;16(S10):S946–S947
🔗 Full Publication

Frequency of PIK3CA Mutations and Therapeutic Outcomes in NSCLC

G. Martos
Journal of Thoracic Oncology. 2021;16(S10):S1161–S1162
🔗 Full Publication

2020 in Hindsight: Newly Diagnosed Lung Cancer Patients in the Time of COVID-19

L. Petersen
Journal of Thoracic Oncology. 2021;16(S10):S1058–S1059
🔗 Full Publication

Evaluating the Influence of Biomarker Status and Precision Treatment on De Novo Metastatic NSCLC Outcomes

M.L. Dean
ACRC
🔗 Full Publication

The Canadian Small Cell Lung Cancer Database (CASCaDe): A Multi-Institutional Real-World Evidence Collaboration

S. Moore
Journal of Thoracic Oncology. 2021;16(S10):S1189
🔗 Full Publication

Intravenous (IV) versus IV/oral route of etoposide administration: impact on real-world SCLC survival outcomes

A. Elegbede
Journal of Thoracic Oncology. 2020;16(S3):S516
🔗 Full Publication

Metastatic NSCLC Outcomes With Guideline-Recommended Treatment By KRAS Subtype

A. Elegbede
Journal of Thoracic Oncology. 2020;16(S3):S436
🔗 Full Publication

A Year Experience With Atezolizumab Plus Chemotherapy For Small Cell Lung Cancer In Alberta, Canada

A. Elegbede
Journal of Thoracic Oncology. 2020;16(S3):S512
🔗 Full Publication

Survival Outcome Comparison in Metastatic SCLC at Diagnosis Versus at Relapse

A. Elegbede
Journal of Thoracic Oncology. 2020;16(S3):S512
🔗 Full Publication

Value of the Lung Immune Prognostic Index (LIPI) As a Prognostic Tool for Real-World Patients Treated for Mutation-Positive Metastatic NSCLC

A.J.W. Gibson
Journal of Thoracic Oncology. 2020;16(S3):S206
🔗 Full Publication

Prognostic Role of the Systemic Immune-Inflammatory Index (SII) in Driver-Mutation Positive NSCLC

A.J.W. Gibson
Journal of Thoracic Oncology. 2020;16(S3):S593
🔗 Full Publication

Real World Outcomes in EGFR-Mutant Relapsed and De Novo Stage IV NSCLC

A.J.W. Gibson
Journal of Thoracic Oncology. 2020;16(S3):S693
🔗 Full Publication

Impact of Number and Location of Metastatic Sites on Survival in Stage IV ICI-Treated NSCLC

A.J.W. Gibson
Journal of Thoracic Oncology. 2020;16(S3):S348
🔗 Full Publication

Early Mortality Associated Factors With Immune Checkpoint Inhibition in Real-World Canadian NSCLC Patients

A.J.W. Gibson
Journal of Thoracic Oncology. 2020;16(S3):S348
🔗 Full Publication

Changing Survival and Treatment Patterns in Patients with Stage IV NSCLC in Alberta, Canada

M. Anaka
Journal of Thoracic Oncology. 2020;16(S3):S286–S287
🔗 Full Publication

Age-Related Outcomes of First-Line Pembrolizumab in a Real-World NSCLC Cohort

S. Dolter
Journal of Thoracic Oncology. 2020;16(S3):S290
🔗 Full Publication

SCLC Treatment Uptake and Survival Outcomes: A 2-Year Comparison Between 2 Tertiary Referral Centers in Alberta, Canada

A. Elegbede
Journal of Thoracic Oncology. 2019;14(S10):S1016–S1017
🔗 Full Publication

Factors Associated with Survival Outcomes Among Relapsed SCLC Diagnosed at a Canadian Cancer Centre

A. Elegbede
Journal of Thoracic Oncology. 2019;14(S10):S1020–S1021
🔗 Full Publication

Sex and Age-Associated Survival Following Resected Early Stage NSCLC

A.J.W. Gibson
Journal of Thoracic Oncology. 2019;14(S10):S619–S620
🔗 Full Publication

Treatment Uptake and Outcomes of Elderly Stage III NSCLC Patients: A 15-Year Retrospective Real-World Study

A.J.W. Gibson
Journal of Thoracic Oncology. 2019;14(S10):S869–S870
🔗 Full Publication

Seq-ing a Better Way to Detect PD-L1 in NSCLC

L. Petersen
Journal of Thoracic Oncology. 2019;14(S10):S720
🔗 Full Publication

From a Systematic Review to Real World Evidence: Integrating Gender as a Clinical Risk Factor in NSCLC

N. Alsaadoun
Journal of Thoracic Oncology. 2019;14(S10):S600
🔗 Full Publication

Improved Outcome in Female Stage III NSCLC Diagnoses Is Driven by Non-Curative Intent Treatment, and Adenocarcinoma Histology

N. Alsaadoun
Journal of Thoracic Oncology. 2019;14(S10):S903–S904
🔗 Full Publication

Development and Validation of a Gene Expression-Based Prognostic Signature in Early-Stage Squamous Cell Carcinoma of the Lung

P. Bose
Journal of Thoracic Oncology. 2019;14(S10):S263–S264
🔗 Full Publication

Real-World Management and Outcomes of Uncommon EGFR Mutation-Positive NSCLC Patients at Two Tertiary Canadian Cancer Centres

R. Tudor
Journal of Thoracic Oncology. 2019;14(S10):S839–S840
🔗 Full Publication

Gender and Systemic Treatment Patterns: Impacts on the Overall Survival of Stage IV NSCLC 2010–2014 Diagnoses

A. Elegbede
Journal of Thoracic Oncology. 2018;13(S10):S675
🔗 Full PDF on JTO

Patterns of Curative Chemo-Radiotherapy Regimen and Impacts on the Outcome of Limited Stage SCLC in a Canadian Institution: 2010–2015 Diagnoses

A. Elegbede
Journal of Thoracic Oncology. 2018;13(S10):S577
🔗 JTO full‑text abstract

2010–2015 Extensive Stage SCLC Diagnoses in a Canadian Institution: Baseline Characteristics That Impact on the Overall Survival

A. Elegbede
Journal of Thoracic Oncology. 2018;13(S10):S577
🔗 Full PDF on JTO

CXCR4 Overexpression is Associated with Poor Survival Outcome After Recurrence in Early Stage NSCLC Patients

A. Fung
Journal of Thoracic Oncology. 2018;13(S10):S918
🔗 JTO abstract/full‑text supplement page

Number, Rather Than Location of Metastases, Dictates Outcome in Stage IV, M1b, NSCLC

A.J.W. Gibson
Journal of Thoracic Oncology. 2018;13(S10):S669–S670
🔗 JTO abstract/full‑text supplement page

Factors Associated with Long-Term Survival of Stage IV NSCLC Patients on First-Line EGFR-Targeting Therapy

A.J.W. Gibson
Journal of Thoracic Oncology. 2018;13(S10):S979–S980
🔗 JTO PDF (supplement)

Factors Associated with Early Mortality in NSCLC Patients Following Systemic Anti-Cancer Treatment

A.J.W. Gibson
Journal of Thoracic Oncology. 2018;13(S10):S406–S407
🔗 Full‑text abstract on JTO

Transcriptome Profiling for Subtyping NSCLC: Off the Beaten Path(Ologist)

L. Petersen
Journal of Thoracic Oncology. 2018;13(S10):S954
🔗 JTO PDF (supplement)

Heterogeneity, Prevalence and Prognostic Significance of PD-L1 Expression in Early Resected NSCLC

M. Dean
Journal of Thoracic Oncology. 2018;13(S10):S986–S987
🔗 Full Publication

Adenocarcinoma of the Lung: The Woman’s Cancer?

N. Alsaadoun
Journal of Thoracic Oncology. 2018;13(S10):S666–S667
🔗 JTO full‑text abstract

Clinical Features and Outcomes of NSCLC Patients with Uncommon EGFR Mutations Treated with EGFR-TKIs

R. Tudor
Journal of Thoracic Oncology. 2018;13(S10):S590–S591
🔗 Full Publication

Survival Benefits and Associated Prognostic Factors among Young NSCLC Patients

A. D’Silva
Journal of Thoracic Oncology. 2017;12(S11):S1988.
🔗 Full Publication

BRG1 and p53 Expression in Resected Stage I – III Non-Small Cell Lung Cancer

A. Elegbede
Journal of Thoracic Oncology. 2017;12(S11):S2125.
🔗 Full Publication

Distribution of Metastatic Disease in Survival Outliers with Stage IV Non-Small Cell Lung Cancer

A. Fung
Journal of Thoracic Oncology. 2017;12(S11):S2078–S2079.
🔗 Full Publication

Clinical Characteristics of Survival with De Novo Versus Relapsed Metastatic Non-Small Cell Lung Cancer

A.J.W. Gibson
Journal of Thoracic Oncology. 2017;12(S11):S2087.
🔗 Full Publication

30-Day Mortality Following Systemic Anti-Cancer Treatment for NSCLC at a Single Canadian Cancer Centre

A.J.W. Gibson
Journal of Thoracic Oncology. 2017;12(S11):S1967.
🔗 JTO full-text abstract

Comparison of Clinical Characteristics and Survival of Lung Cancer Patients in a Canadian Province and in the United States According to Insurance Status

A. Matutino
Journal of Thoracic Oncology. 2018;13(S4):S22–S23.
🔗 JTO full-text abstract/PDF

Accelerometer-Determined Physical Activity and Sedentary Time among Lung Cancer Survivors

Adrijana D’Silva
Journal of Thoracic Oncology. 2017;12(S1):S476–S477.
🔗 Full‑text abstract on JTO (JTO)

Clinical Characteristics of Survival Outliers in Stage IV Adenocarcinoma Lung Cancer Patients

Andrea Fung
Journal of Thoracic Oncology. 2017;12(S1):S679.
🔗 Full Publication

Overall Survival Characterization of Incidental N2 Non-Small Cell Lung Cancer over 14 Years at a Single Canadian Institution

Cara Van Der Merwe
Journal of Thoracic Oncology. 2017;12(S1):S369–S370.
🔗 JTO full-text abstract

Platin Sensitivity and ATM-Deficiency in Non-Small Cell Lung Cancer

J. Moore
Journal of Thoracic Oncology. 2017;12(S11):S2265.
🔗 JTO full‑text abstract

Platin Induced Phosphorylation of ATM and ATM-Deficiency as a Predictive Marker of Platin Sensitivity in Non-Small Cell Lung Cancer

Jarrett Moore
Journal of Thoracic Oncology. 2017;12(S1):S843.
🔗 Full Publication

ATM Mutation as a Predictor for Mutation Burden in NSCLC

L. Petersen
Journal of Thoracic Oncology. 2017;12(S11):S1929.
🔗 Full Publication

Transcriptome Analysis of ATM-Deficient NSCLC

Lars Petersen
Journal of Thoracic Oncology. 2017;12(S1):S265.
🔗 JTO full‑text abstract

ATM Mutations in Lung Cancer Correlate to Higher Mutation Rates

Lars Petersen
Journal of Thoracic Oncology. 2017;12(S1):S541.
🔗 Full Publication

Sex-Based Disparities in NSCLC: An Evidence-Based Study

N. Alsaadoun
Journal of Thoracic Oncology. 2017;12(S11):S1988.
🔗 JTO full‑text abstract

Gender Disparities in Non-Small Cell Lung Cancer: A Systematic Review

Noor Alsaadoun
Journal of Thoracic Oncology. 2017;12(S1):S352–S353.
🔗 JTO full‑text abstract

Gender and Ethnicity Influence on Outcome in EGFRmut+ NSCLC Patients Treated at a Single Canadian Institution

Roxana Tudor
Journal of Thoracic Oncology. 2017;12(S1):S1197–S1198.
🔗 JTO full‑text abstract (jto.org)

Sex Differences in CXCR4-Dependent Motility of Non-Small Cell Lung Cancer Cells

Shannon Otsuka
Journal of Thoracic Oncology. 2017;12(S1):S476–S477

🔗 JTO full‑text abstract

Development of Assay Controls for PD-L1 Testing by Immunohistochemistry

M.L. Dean, Vincent Law, Emeka Enwere, Don Morris, Michelle Dean
Molecular Medicine Tri-Conference 2016.

Analysis of EGFR Gene Copy Number, EGFR Mutations, KRAS Mutations, and EGFR Expression in a Cohort of Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors at a North American Institution

Alan K. Box
Journal of Thoracic Oncology. 2007;2(S8):S516.
🔗 Full Publication

Reduction of Non-Small Cell Lung Cancer (NSCLC) Cell Line Migration in Vitro by Inhibition of the CXCR4/SDF-1 Axis; A Novel Approach to Preventing Dissemination of Early Stage NSCLC

Shannon Otsuka
Journal of Thoracic Oncology. 2007;2(S8):S548–S549.
🔗 Full Publication

Similar Characteristics of Responders Treated with the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKI) Gefitinib and Erlotinib for Advanced Non-Small Cell Lung Cancer (NSCLC) in a Single Canadian Institution

Institution — Shannon Otsuka
Journal of Thoracic Oncology. 2007;2(S8):S732

🔗 JTO full‑text abstract (Journal of Transport and Land Use)